Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…
Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more
Estimated
~$10 – $7,500
Marcela V. Maus, M.D.,Ph.D.NCT06026319
Phase 1
A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refra…
B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Estimated
~$10 – $8,750
Vironexis Biotherapeutics Inc.NCT06533579
Phase 2
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line trea…
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Estimated
~$10 – $6,250
Brown UniversityNCT07502872
Phase 1
Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. T…
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Estimated
~$10 – $7,500
Paolo Caimi, MDNCT07225439